Publications by authors named "A Torre-Delgadillo"
Introduction Malocclusion, a prevalent oral health concern, significantly impacts both functional abilities and psychosocial well-being. The Dental Aesthetic Index (DAI) is widely used to assess malocclusion severity and orthodontic treatment needs. This study aims to evaluate the prevalence of orthodontic treatment needs based on the DAI in a Mexican population, considering factors such as gender, oral hygiene, and age range.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the link between myostatin levels, sarcopenia, and the development of acute-on-chronic liver failure (ACLF) in cirrhosis patients, finding a progressive decrease in myostatin as cirrhosis worsens.
- Out of 186 patients, 27.9% experienced acute decompensation and 25.8% developed ACLF, with infections being a common trigger.
- Myostatin levels were found to be predictive of ACLF and patient survival, highlighting its potential role in monitoring and managing cirrhosis progression.
Introduction: Autoimmune hepatitis (AIH) is associated with periportal infiltration by plasma cells. Plasma cell detection is routinely performed through hematoxylin and eosin (H&E) staining. The present study aimed to assess the utility of CD138, an immunohistochemical plasma cell marker, in the evaluation of AIH.
View Article and Find Full Text PDFSofosbuvir-velpatasvir in Mexican patients with hepatitis C: A retrospective review.
Rev Gastroenterol Mex (Engl Ed)
February 2022
Introduction: The sofosbuvir-velpatasvir (SOF/VEL) combination is a direct-acting antiviral therapy that is authorized and available in Mexico, making the performance of a real-world multicenter study that evaluates the sustained virologic response at 12 weeks post-treatment a relevant undertaking.
Methods: A retrospective review of the case records of 241 patients seen at 20 hospitals in Mexico was conducted to assess hepatitis C treatment with the SOF/VEL combination (n = 231) and the sofosbuvir/velpatasvir/ribavirin (SOF/VEL/RBV) combination (n = 10). The primary efficacy endpoint was the percentage of patients that achieved SVR at 12 weeks after the end of treatment.